Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Read more
Sign In
June 16, 202112:43 PM PDTLast Updated a month ago
Healthcare & Pharmaceuticals
Regeneron antibodies help asymptomatic and hospitalized patients; some lymph node cancers limit vaccine response
Nancy Lapid

7 minute read
The word "COVID-19" is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration
June 16 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
Regeneron COVID-19 drug helps hardly sick and hospitalized patients
An antibody cocktail from Regeneron Pharmaceuticals Inc (REGN.O) and Roche (ROG.S) showed benefits for a wide range of COVID-19 patients, from those without symptoms to hospitalized patients whose immune systems have not mounted a natural antibody response to the virus, two research teams reported on medRxiv ahead of peer review. The cocktail, REGEN-COV, is already being used intravenously in the United States to keep symptomatic COVID-19 patients out of the hospital. In a large new trial in U.S. adults and adolescents with coronavirus detected in the nose but no symptoms, researchers compared the effects of a single under-the-skin injection of the drug to a placebo. The results, released on Monday, showed the treatment cut patients' risk of developing symptoms by 32%. It also reduced the amount of virus patients carry, said study leader Meagan O'Brien of Regeneron. When symptoms did develop, they resolved five-to-six days faster with the drug. No one who got the drug required an emergency room visit or hospitalization, compared to six people in the placebo group. In a separate study from the UK released on Wednesday, intravenous treatment with REGEN-COV reduced the risk of death in hospitalized patients whose immune systems had not produced antibodies to the coronavirus. Treatment also shortened these patients' hospital stays and reduced their odds of needing mechanical ventilation. No benefit was seen, however, in patients who already had their own antibodies. (​https://bit.ly/3iM3qqb;​https://bit.ly/3zwiqyp;​https://reut.rs/3iIw7Es​)
Some lymph node cancers limit COVID-19 vaccine responses
Some patients with lymph node cancers will have good antibody responses to COVID-19 vaccines, but others will need further protection, according to new data. The UK PROSECO study tested antibody levels in 129 lymphoma patients after their first and/or second dose of the Pfizer/BioNTech (PFE.N), or AstraZeneca (AZN.L) vaccines. Responses were mixed, researchers reported on Saturday on medRxiv ahead of peer review. Patients vaccinated during or within six months after treatment for their blood cancer were unlikely to develop good antibody responses, researchers found. These patients need to be revaccinated, said study leader Dr. Sean Hua Lim of the University of Southampton. Among patients who had never received treatment, or who had completed treatment more than six months prior, those with curable lymphomas responded well to the vaccine. All five with Hodgkin lymphoma, and seven of eight with aggressive B-cell lymphomas developed strong antibody responses. But 18 of 36 patients with incurable indolent lymphomas, like follicular lymphoma, had lower antibody levels than other patient groups. For these patients, "further measures such as boosting with a different vaccine, or prophylactic treatment with antibodies should be considered," Lim said. (​https://bit.ly/3iJewvZ​)
Coronavirus may have been in U.S. in late December
At least seven people in five U.S. states were infected with the novel coronavirus weeks before the states reported their first cases, a large government study suggests. Researchers who analyzed more than 24,000 blood samples taken for a National Institutes of Health research program between Jan. 2 and March 18, 2020 found that samples showing antibodies to the coronavirus came as early as Jan. 7 from participants in Illinois, Massachusetts, Mississippi, Pennsylvania and Wisconsin. They do not know whether people with positive samples became infected during travel or while in their own communities. They do know, however, that people with antibodies were likely exposed to the virus weeks before their sample was taken, as antibodies do not appear until about two weeks of infection, according to a report published on Tuesday in Clinical Infectious Diseases. The data suggest the virus was in U.S. states far from the initial hotspots and areas that were considered its points of entry into the country, the authors said. The researchers followed U.S. Centers for Disease Control and Prevention guidelines for minimizing false-positive results. Experts not involved in the study said more research is needed to confirm that the positive early samples are not due to common cold antibodies. (​https://bit.ly/3pYoEmm;​https://reut.rs/3ww3uOY​)
Flu shots, COVID-19 vaccine can be given together
People may be able to get an annual flu shot and a COVID-19 vaccine at the same time, a UK study suggests. The 431 study participants all received influenza vaccines manufactured by Seqirus, a unit of CSL Ltd (CSL.AX). They also received either the not-yet-approved COVID-19 vaccine from Novavax Inc (NVAX.O), which has been highly effective in clinical trials, or a placebo. The results, posted on Sunday on medRxiv and submitted for review to The Lancet, suggest the two vaccines do not interfere with each other. The efficacy of both the influenza vaccine and the Novavax vaccine "appeared to be preserved," Seqirus said in a statement. "No additional safety concerns were found with co-administration and adverse events were similar to the incidence and severity for each vaccine when administered separately," it said. (​https://bit.ly/3zwwpnT;​https://reut.rs/3gD4ASe​)
Open https://tmsnrt.rs/3c7R3Bl in an external browser for a Reuters graphic on vaccines in development.
Reporting by Nancy Lapid, Alistair Smout and Amruta Khandekar; Editing by Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles.
More from Reuters
Play video on original page
Read Next
Asia Pacific
Malaysia reports record 17,786 coronavirus cases
1:08 AM PDT
Asia Pacific
Tokyo's daily COVID-19 infections hit new record of 4,058
1:03 AM PDT
Uganda partially eases COVID-19 containment measures
12:58 AM PDT
Asia Pacific
COVID-19 cases surge in Sydney as police cordon deters protest
12:43 AM PDT

Sign up for our newsletter
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Healthcare & Pharmaceuticals
Healthcare & Pharmaceuticals · July 30, 2021 · 7:00 PM PDT
'The war has changed,' CDC says, calling for new response to Delta variant
The war against COVID-19 has changed because of the highly contagious Delta variant, the U.S. Centers for Disease Control said, proposing a clearer message, mandatory vaccines for health workers and a return to universal masking.
Healthcare & Pharmaceuticals
COVID-19 cases surge in Sydney as police cordon deters protest
12:43 AM PDT
Healthcare & Pharmaceuticals
Hard-won gains at risk as Delta variant spreads- WHO
July 30, 2021
Healthcare & Pharmaceuticals
Johnson & Johnson not liable for Illinois woman's death in talc case
July 30, 2021
Healthcare & Pharmaceuticals
U.S. CDC chief says there will be no federal mandate on COVID-19 vaccine
July 30, 2021
About Reuters
About Reuters
Reuters News Agency
Brand Attribution Guidelines
Reuters Leadership
Reuters Fact Check
Reuters Diversity Report
Stay Informed
Download the App
Information you can trust
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Follow Us
Thomson Reuters Products
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Refinitiv Products
Information, analytics and exclusive news on financial markets - delivered in an intuitive desktop and mobile interface.
Refinitiv Data Platform
Access to real-time, reference, and non-real time data in the cloud to power your enterprise.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
Advertise With Us
Advertising Guidelines
Terms of Use
Site Feedback

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved